JB

Joseph Baron

Co-Founder, Director & CEO

Atacama Therapeutics

Therapeutic Areas

Atacama Therapeutics Pipeline

DrugIndicationPhase
AT-5214 (dexmecamylamine)Acne Vulgaris (moderate to severe)Phase 2
Early Stage ProgramsDermatology (unspecified)Preclinical